Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share.
The report summarises the commercial potential of Orthocell’s novel orthopaedic repair technology and its advanced product pipeline, as well as the competitive advantages and revenue opportunities associated with its Striate™ and Remplir™ products – especially in the US.
Describing the Company as being on the cusp of widespread adoption, the author noted:
“The wait looks to be over for Orthocell investors. It typically takes 7-12 years for a novel medical treatment to contribute meaningful revenues. It is now 8 years since the Company commenced the pilot CelGro study. With the validation of the CelGro platform from the BioHorizons deal and scale up of manufacturing capacity recently completed, the transition to a global medical device manufacturer has begun.”
The report also highlights the strengths of the leadership team, noting “the board and executive team of Orthocell contains the right mix of scientific and commercial expertise for the next phase of growth.”